<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916640</url>
  </required_header>
  <id_info>
    <org_study_id>CT034-ADO09</org_study_id>
    <nct_id>NCT03916640</nct_id>
  </id_info>
  <brief_title>A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a monocentric, randomised, double-blind, active comparator, controlled,
      3-period cross-over trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this monocentric, randomised, double-blind, active comparator, controlled, cross-over
      trial, each patient will be randomly allocated to a sequence of three treatments: one single
      dose of the co-formulation of insulin analog and pramlintide (also called ADO09),
      simultaneous separate injections of pramlintide and human insulin and one single dose of
      insulin lispro. To keep the blinding in this trial, a placebo injection will be given in
      addition to the ADO09 formulation and insulin lispro dose for a total of 2 injections per
      dosing visit. During each visit, meal test procedures will be performed and subjects will
      stay at the clinical centre until post-dose follow-up period has been terminated. IMP
      administration will be done subcutaneously immediately prior to test meal intake.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CmaxPram</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Maximum pramlintide concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCPram 0-8h</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Area under the pramlintide concentration-time curve from 0-8 hours after IMP administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CmaxIns</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Maximum insulin analog concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCIns 0-8h</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Area under the insulin analog concentration-time curve from 0-8 hours after IMP administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of pramlintide</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Area under the pramlintide concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of insulins</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Area under the insulins concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose pharmacodynamics</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Area under the blood glucose concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (Adverse Events recording)</measure>
    <time_frame>From 0 to 8 hours</time_frame>
    <description>Number of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Co-formulation of insulin analog and pramlintide (ADO09)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of ADO09 formulation + injection of placebo (0.9% NaCl) to ensure double dummy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humulin® + Symlin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simultaneous, separate subcutaneous injections of human insulin and pramlintide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection of insulin lispro + injection of placebo (0.9% NaCl) to ensure double dummy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADO09 formulation</intervention_name>
    <description>Subcutaneous injection of ADO09 formulation</description>
    <arm_group_label>Co-formulation of insulin analog and pramlintide (ADO09)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection of 0.9% NaCl</description>
    <arm_group_label>Co-formulation of insulin analog and pramlintide (ADO09)</arm_group_label>
    <arm_group_label>Humalog®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symlin®</intervention_name>
    <description>Subcutaneous injection of pramlintide</description>
    <arm_group_label>Humulin® + Symlin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humulin®</intervention_name>
    <description>Subcutaneous injection of human insulin</description>
    <arm_group_label>Humulin® + Symlin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <description>Subcutaneous injection of insulin lispro</description>
    <arm_group_label>Humalog®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes Mellitus (as diagnosed clinically) ≥ 12 months

          -  Treated with multiple daily injection ≥ 12 months

          -  Treated with insulin glargine U100 or U300 or insulin detemir at screening

          -  Fasting C-peptide ≤ 0.30 nmol/L

          -  BMI: 18.5-28.0 kg/m² (both inclusive)

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to IMPs, paracetamol or related products

          -  Type 2 Diabetes Mellitus

          -  Clinically significant abnormal haematology, biochemistry or urinalysis screening
             test, as judged by the investigator considering the underlying disease

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the investigator

          -  Known slowing of gastric emptying, including gastroparesis and or gastrointestinal
             surgery that in the opinion of the investigator, might change gastrointestinal
             motility and food absorption

          -  Intake of medication known to affect gastrointestinal motility, including but not
             limited to erythromycin, metoclopramide, cisapride, cholestyramine or colestipol
             within 4 weeks before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

